Abstract 732P
Background
Cabozantinib (cabo) is approved in Europe for the treatment of patients (pts) with metastatic renal cell carcinoma (mRCC) in treatment-naïve adults with intermediate or poor risk prognosis, or following prior VEGFR-targeted therapy. CABOREAL describes the use of cabo in a real-life setting in the largest unselected population to date of pts with mRCC who have received at least one dose of cabo. In this post hoc analysis, we assessed the patterns of cabo use and the activity of cabo in pts with non-clear cell RCC (nccRCC) and sarcomatoid renal cell carcinoma (sRCC) histology.
Methods
In CABOREAL (NTC03744585), data were retrospectively collected from 26 centres in France. Pts were treated with cabo via the French Early Access Program from Sep 12, 2016 to Feb 19, 2018. These subgroup analyses were descriptive.
Results
Among 410 pts enrolled in CABOREAL, 59 were identified with nccRCC: papillary (pRCC) type I in 12 pts (20.3%), pRCC type II in 23 pts (39.0%), chromophobe (chRCC) in 6 pts (10.2%), collecting duct carcinoma (CDC) in 1 pt (1.7%) and other “unclassified” in 5 pts (8.5%). 32 pts had sRCC. Twelve pts (20.3%) were excluded from the analysis with unknown histological type mainly due to the retrospective collection of data. Patterns of cabo use, duration of cabo treatment and overall survival according to histological subtypes are summarized in the table.
Conclusions
According to this subanalysis, cabozantinib appears to have effectiveness in nccRCC, particularly in pRCC type I. As with other antiangiogenic therapies, the prognosis and duration of treatment appears to be most favourable for patients with pRCC type I. Table: 732P
| Histology | Starting dose at 60mg % | Average daily dose Median MG | Dose reduction % | Duration of cabo treatment Median Months [range] | Overall survival Median Months | |
| nccRCC | pRCC type I | 81.8 | 36.8 | 81.8 | 15.4 [3.2-29.1] | 16 |
| pRCC type II | 82.6 | 44.3 | 47.8 | 4.5 [0.4-22.6] | 8.1 | |
| chRCC | 66.7 | 34.7 | 83.3 | 8.7 [1.5-17.4] | Not estimable | |
| CDC | 100.0 | 60.0 | 0.0 | - | - | |
| Unclassified | 80.0 | 44.4 | 60.0 | 5.8 [0.7-12.6] | 5.6 | |
| sRCC | 81.3 | 44.7 | 40.6 | 5.6 [0.3-26.6] | 8.1 |
Clinical trial identification
NTC03744585.
Editorial acknowledgement
Legal entity responsible for the study
Ipsen.
Funding
Ipsen.
Disclosure
A. Fléchon: Honoraria (self), Travel/Accommodation/Expenses: BMS; Honoraria (self), Travel/Accommodation/Expenses: Pfizer; Honoraria (self), Travel/Accommodation/Expenses: Bayer; Honoraria (self), Travel/Accommodation/Expenses: Novartis; Honoraria (self), Travel/Accommodation/Expenses: Ipsen. C.M. Chevreau: Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: BMS; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Ipsen; Honoraria (self), Advisory/Consultancy: Novartis. D. Topart: Honoraria (self), Travel/Accommodation/Expenses: Pfizer; Travel/Accommodation/Expenses: Ipsen; Honoraria (self): Janssen; Honoraria (self): Sanofi; Honoraria (self): BMS. G. Gravis: Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses: Pfizer; Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses: BMS; Honoraria (institution), Travel/Accommodation/Expenses: MSD; Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses: AstraZeneca; Honoraria (institution): Astella; Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses: Janssen; Honoraria (institution), Advisory/Consultancy: Bayer; Advisory/Consultancy, Travel/Accommodation/Expenses: Sanofi; Advisory/Consultancy, Travel/Accommodation/Expenses: Ipsen. S. Oudard: Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Merck; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: BMS; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: AstraZeneca; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Pfizer; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Bayer; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Novartis; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Janssen; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Astellas; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Sanofi. J.M. Tourani: Honoraria (self), Travel/Accommodation/Expenses: Ipsen. L. Geoffrois: Honoraria (self), Travel/Accommodation/Expenses: Ipsen; Honoraria (self), Travel/Accommodation/Expenses: BMS; Honoraria (self), Travel/Accommodation/Expenses: MSD; Honoraria (self), Research grant/Funding (institution): Novartis; Honoraria (self): AstraZeneca. A. Thiery-Vuillemin: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Pfizer; Honoraria (self), Advisory/Consultancy: AstraZeneca; Honoraria (self), Advisory/Consultancy: Sanofi; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Janssen; Honoraria (self), Advisory/Consultancy: Novartis; Honoraria (self), Advisory/Consultancy: Ipsen; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Roche/Genentech; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: BMS; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: MSD; Honoraria (self), Advisory/Consultancy: Astellas. P. Barthélémy: Advisory/Consultancy, Travel/Accommodation/Expenses: BMS; Advisory/Consultancy, Travel/Accommodation/Expenses: Pfizer; Advisory/Consultancy: Janssen Cilag; Travel/Accommodation/Expenses: Janssen; Advisory/Consultancy, Travel/Accommodation/Expenses: Sanofi; Advisory/Consultancy, Travel/Accommodation/Expenses: Ipsen; Advisory/Consultancy, Travel/Accommodation/Expenses: MSD; Advisory/Consultancy: EusaPharma; Advisory/Consultancy: Novartis; Advisory/Consultancy, Travel/Accommodation/Expenses: Roche; Advisory/Consultancy, Travel/Accommodation/Expenses: Astellas. S. Ladoire: Advisory/Consultancy, Travel/Accommodation/Expenses: Pfizer; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Novartis; Advisory/Consultancy, Travel/Accommodation/Expenses: BMS; Advisory/Consultancy, Travel/Accommodation/Expenses: Ipsen; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche. B. Laguerre: Travel/Accommodation/Expenses: Pfizer; Honoraria (self): BMS; Honoraria (self): Roche; Honoraria (self): Ipsen; Honoraria (self): MSD. R. Bourouina: Full/Part-time employment: Ipsen. V. Perrot: Full/Part-time employment: Ipsen. B. Escudier: Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: BMS; Advisory/Consultancy, Travel/Accommodation/Expenses: MSD; Advisory/Consultancy: Novartis; Advisory/Consultancy: Ipsen/Exelixis; Advisory/Consultancy: Roche; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Merck; Advisory/Consultancy: AstraZeneca. M. Gross-Goupil: Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Ipsen; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Roche; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: BMS; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: MSD; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Pfizer; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Novartis; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: AstraZeneca. L. Albiges: Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: BMS; Advisory/Consultancy, Travel/Accommodation/Expenses: MSD; Advisory/Consultancy: Novartis; Advisory/Consultancy: Amgen; Advisory/Consultancy: Ipsen; Advisory/Consultancy: Roche; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Merck; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Exelixis; Advisory/Consultancy: Peloton Therapeutics; Advisory/Consultancy: Corvus Pharmaceuticals. All other authors have declared no conflicts of interest.